The 10-second takeaway
For the quarter ended Nov. 30 (Q2), Neogen missed on revenues and whiffed on earnings per share.
Compared to the prior-year quarter, revenue increased slightly, and earnings per share dropped significantly.
Margins dropped across the board.
Neogen booked revenue of $45 million. The five analysts polled by S&P Capital IQ foresaw a top line of $47 million. Sales were 2.2% higher than the prior-year quarter's $44 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS came in at $0.22. The four earnings estimates compiled by S&P Capital IQ forecast $0.26 per share. GAAP EPS of $0.22 for Q2 were 15% lower than the prior-year quarter's $0.26 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 50.5%, 70 basis points worse than the prior-year quarter. Operating margin was 18.1%, 380 basis points worse than the prior-year quarter. Net margin was 11.7%, 220 basis points worse than the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods.
What does the future hold?
Next quarter's average estimate for revenue is $45 million. On the bottom line, the average EPS estimate is $0.22.
Next year's average estimate for revenue is $183 million. The average EPS estimate is $0.93.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 258 members out of 266 rating the stock outperform and eight members rating it underperform. Among 76 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), all 76 give Neogen a green thumbs-up, and none give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neogen is outperform, with an average price target of $39.60.
- Add Neogen to My Watchlist.